Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $40.67.

Several analysts recently weighed in on SLN shares. BMO Capital Markets dropped their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Morgan Stanley cut their price objective on shares of Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a report on Tuesday, March 4th.

Hedge Funds Weigh In On Silence Therapeutics

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of Silence Therapeutics during the 4th quarter worth approximately $26,000. GAMMA Investing LLC raised its position in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares in the last quarter. Barclays PLC lifted its stake in Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at $69,000. Finally, Virtus ETF Advisers LLC increased its stake in shares of Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after purchasing an additional 6,098 shares during the last quarter. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Stock Down 3.8 %

Shares of SLN stock opened at $3.56 on Monday. Silence Therapeutics has a 12-month low of $3.53 and a 12-month high of $24.38. The company has a market capitalization of $106.55 million, a PE ratio of -2.27 and a beta of 1.08. The firm has a 50 day moving average price of $4.83 and a two-hundred day moving average price of $10.33.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.